Market Snapshot

Picture2_Asia-Pacific Cancer Therapy Market

Study Period:

2016-2024

Base Year:

2018

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Asia-Pacific Cancer Therapy Market

The Asia-Pacific cancer therapy market will show rapid growth due to the rising prevalence of cancer, growing government initiatives for cancer awareness and increasing patient assistance programs (PAPs).

Lung, stomach, colorectum, liver, and oesophagus are the most common types of cancer in China. The increasing prevalence of cancer burden and thus, cancer therapies is due to a number of factors, including population growth, ageing, environmental pollution and unhealthy dietary habits. In addition, cigarette smoking, in particular, has also continued to be prevalent in the Asia Pacific region. The rising prevalence of cancer, thus helps the market to grow over the forecast period.

There are also several awareness programs initiated across the Asia Pacific region. For instance, the Indian government has recently announced the Ayushman India National Health Security Scheme under which the patients of cancer can take advantage of up to INR 5 lakhs, admitted without hospitalization and chemotherapy, medicines and screening expenses will be covered. Hence the presence of various government initiatives to curb the increasing prevalence of cancer is expected to drive the overall growth of the market.

Scope of the Report

As per the scope of the report, cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. These therapies include surgery, radiation therapy, chemotherapy, immunotherapy, etc.

By Treatment Type
		Chemotherapy
		Target Therapy
		Immunotherapy
		Hormone Therapy
		Other Treatment Types

By Cancer Type
		Blood Cancer
		Breast Cancer
		Prostate Cancer
		Gastrointestinal Cancer
		Gynecologic Cancer
		Respiratory/Lung Cancer
		Other Cancer Types

By End-User
		Hospitals
		Specialty Clinics
		Radiation Center

Geography

Asia Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Target Therapy Segment is Expected to Show the Highest Growth During the Forecast Period

The target therapy segment is expected to show the highest CAGR during the forecast period. The targeted therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells.

The other major factors driving the growth of the segment are an increase in R&D and the rising prevalence of various types of cancer across the globe. Targeted therapy is a treatment for cancer that is unlike the traditional chemotherapy used for cancer. The drugs for target therapy work by targeting the specific genes or proteins that are present in the cancer cells.

Picture3_Asia-Pacific Cancer Therapy Market

To understand key trends, Download Sample Report

Competitive Landscape

The cancer therapy market is highly competitive and consists of several players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with cheaper prices.

Major Players

* Complete list of players covered available in the table of contents below

Picture4_Asia-Pacific Cancer Therapy Market

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Rising Prevalence of Cancer
  2. 4.2.2 Growing Government Initiatives for Cancer Awareness
  3. 4.2.3 Increasing Patient Assistance Programs (PAPs)
3. 4.3 Market Restraints
  1. 4.3.1 High Cost of Cancer Therapies
  2. 4.3.2 Fluctuation in Reimbursement Policies
4. 4.4 Porter's Five Force Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 By Treatment Type
  1. 5.1.1 Chemotherapy
  2. 5.1.2 Target Therapy
  3. 5.1.3 Immunotherapy
  4. 5.1.4 Hormone Therapy
  5. 5.1.5 Other Treatment Types
2. 5.2 By Cancer Type
  1. 5.2.1 Blood Cancer
  2. 5.2.2 Breast Cancer
  3. 5.2.3 Prostate Cancer
  4. 5.2.4 Gastrointestinal Cancer
  5. 5.2.5 Gynecologic Cancer
  6. 5.2.6 Respiratory/Lung Cancer
  7. 5.2.7 Other Cancer Types
3. 5.3 By End-User
  1. 5.3.1 Hospitals
  2. 5.3.2 Specialty Clinics
  3. 5.3.3 Radiation Center
4. 5.4 Geography
  1. 5.4.1 Asia Pacific
    1. 5.4.1.1 China
    2. 5.4.1.2 Japan
    3. 5.4.1.3 India
    4. 5.4.1.4 Australia
    5. 5.4.1.5 South Korea
    6. 5.4.1.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Amgen
  2. 6.1.2 Astra Zeneca
  3. 6.1.3 Bayer AG
  4. 6.1.4 Bristol Myers Squibb Company
  5. 6.1.5 F. Hoffman-La Roche Ltd
  6. 6.1.6 Johnson & Johnson
  7. 6.1.7 Merck & Co. Inc.
  8. 6.1.8 Eli Lilly
  9. 6.1.9 Novartis AG
  10. 6.1.10 Pfizer Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments